Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Unmet medical needs

At Oxurion we are dedicated to finding and developing innovative therapies to meet medical needs in ophthalmology. According to the World Health Organization, chronic eye disorders account for more than 80% of visual impairment cases worldwide, with the majority of them being back of the eye diseases.

Oxurion’s deep scientific commitment to diseases affecting the back of the eye is the foundation of our current pipeline focused on new treatment approaches to retinal disorders including diabetic macular edema (DME).

Read more about back of the eye disorders

We focus on non-VEGF pathways

Our focus on non-VEGF pathways means first and foremost leaving the anti-VEGF pathway. An anti-VEGF is a good product but it does not work for up to 50% of those with DME, meaning there is no effective treatment for them. Exploring non-VEGF pathways might provide a chance to better address the current unmet medical need of those DME patients. 

Read the full article

Unique research pipeline beyond VEGF

Literature data show that patients with DME have elevated levels of plasma kallikrein and that the vitreous level of plasma kallikrein varies less compared to VEGF, making it a potentially more effective target for treating DME.

THR-149 is a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal) with an inhibition constant of 0.22 nM. Through the inhibition of the kallikrein-kinin system (KKS), THR-149 prevents the induction of retinal vascular permeability, inflammation and angiogenesis. Additionally, THR-149 has the potential to reduce retinal vascular micro-hemorrhages and retinal ganlion cell degeneration.

Science leadership team

Our goal: to be a fast and agile biotech company without sacrificing quality. Our strategy: cross-functional teamwork between our preclinical, clinical and medical teams throughout the R&D process.

The medical team is involved from start to end of a program to bring a new drug to market. The preclinical team is responsible for the research targets explored. 

And in all clinical phases, the development team works hard on the regulatory, quality and safety aspects of every program. This collaborative mindset is our key strength, realized under our Science leadership team:

 

Prof Alan Stitt, PhD

Chief Scientific Officer

Prof Stitt was appointed CSO of Oxurion in January 2021, and is currently overlooking all preclinical research at the Company. Alan Stitt holds the McCauley Chair of Experimental Ophthalmology at Queen’s University of Belfast since 2001 and is internationally known for his research in ophthalmology, particularly in the pathogenesis of diabetic retinopathy and age-related retinal disease.  As a member of the Royal Irish Academy (RIA) and a Fellow of the US Association for Research in Vision & Ophthalmology (ARVO), Alan contributes significantly to the international academic community by serving on advisory boards and grant panels, and has a range of editor and editorial board memberships in the ophthalmology arena.  

Exploring non-VEGF pathways might provide a chance to better address the current unmet medical need of up to 50% of DME patients.

- Oxurion Science leadership team